Trials / Completed
CompletedNCT04606784
Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Ampion In Adults With Respiratory Distress Secondary to COVID-19 Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ampio Pharmaceuticals. Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of nebulized Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who have respiratory distress.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ampion | Ampion, nebulized for inhalation |
| OTHER | Standard of Care | Standard of Care |
Timeline
- Start date
- 2020-10-28
- Primary completion
- 2021-06-15
- Completion
- 2021-06-15
- First posted
- 2020-10-28
- Last updated
- 2022-03-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04606784. Inclusion in this directory is not an endorsement.